HONG KONG – In another blow to the operations of multinational pharmaceutical companies in China, Pfizer Inc. may have to suspend its vaccine business temporarily as it shifts from Prevenar 7 to Prevenar 13.
HONG KONG – China has released a draft of its long-awaited first-ever regulations on stem cell studies, which provide guidance for an industry with huge scientific and commercial potential.
HONG KONG – Lack of proper staffing is the main reason for the huge drug approval backlog at the CFDA, which topped 18,000 applications last year. Though the regulator has plans to reduce the backlog in three years, it is facing other issues beyond the staffing problem. And the shortage of staff compounds other problems such as repetitive applications from generic drug manufacturers and the occasional bout of corruption.
SINGAPORE – South Korea and India are likely to remain the leading players in the biosimilars space in Asia and widen the lead they have on China, which remains a distant third.
HONG KONG – Lack of proper staffing is the main reason for the huge drug approval backlog at the CFDA, which topped 18,000 applications last year. Though the regulator has plans to reduce the backlog in three years, it is facing other issues beyond the staffing problem.
HONG KONG – China has released a draft of its long-awaited first-ever regulations on stem cell studies, which provide guidance for an industry with huge scientific and commercial potential.
SINGAPORE – South Korea and India are likely to remain the leading players in the biosimilars space in Asia and widen the lead they have on China, which remains a distant third.
SINGAPORE – Despite a number of advantages as a site for early stage clinical trials, Asia not only lags other regions in the world but the proportion of studies it hosts is actually dropping.
HONG KONG – Marking an important shift in the way the biotech industry operates in Asia, companies are increasingly willing and eager to share information with their peers, governments and industry associations to develop new and more effective immunotherapies.
